News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Volastra Therapeutics dosed the first patient in their Phase I/II clinical trial of VLS-1488
Photo from Volastra Therapeutics/LinkedIn
Nov 3, 2023, 12:06

Volastra Therapeutics dosed the first patient in their Phase I/II clinical trial of VLS-1488

Volastra Therapeutics shared on their LinkedIn page:

”We’ve dosed the first patient in our Phase I/II clinical trial of VLS-1488, our internally discovered KIF18A inhibiting drug designed to treat patients with advanced cancers characterized by high levels of chromosomal instability.”

For more information click here.
Source: Volastra Therapeutics/LinkedIn

cancer clinical trial KIF18A inhibition OncoDaily Oncology VLS-1488 Volastra Therapeutics
Special Coverage
Blog
Aug 3, 2025, 17:38
Pat Soon-Shiong: Trying Hard for the Cancer Community
Blog
Aug 3, 2025, 17:15
Support from Three Young Bakers - World Child Cancer
Science
Aug 3, 2025, 17:14
Jordan Gauthier: B-Cell Maturation Antigen CAR T-Cell Therapy for RRMM
Insight
Aug 3, 2025, 17:02
Dr. Bishal Gyawali – Challenging the Status Quo Award: Yvonne Awards 2025
Insight
Aug 3, 2025, 17:01
Hafsa Elmarrachi: Strategic Synthesis of Breakthrough Clinical Advances in Lung and GI Cancers Presented at ASCO 2022 and 2023
Science
Aug 3, 2025, 16:42
Myeloma Paper of the Day, August 3rd, Suggested by Robert Orlowski
Blog
Aug 3, 2025, 16:34
Nina Niu Sanford: Excited to See Harvey Mamon as Co-Chair of the NCI GI Steering Committee
Blog
Aug 3, 2025, 16:24
William Aird: What Determines the ESR?
Blog
Aug 3, 2025, 16:12
Angela Morabito's Talk at MGH for the American Lung Cancer Screening Initiative - Florez Lab
Blog
Aug 3, 2025, 16:06
Bridging the Gap in the Diagnosis and Management of Lung Cancer - The Institute of Cancer and Crisis
Blog
Aug 3, 2025, 16:01
Amol Akhade: The Seduction of Significance
Blog
Aug 3, 2025, 15:57
Shaban Juma: Registration and Abstract Submission are Open For TICC2025